A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is…
Last month, the FDA announced their approval of Amjevita, a biosimilar to AbbVie's Humira. Humira posted global sales exceeding $14 billion in 2015, and its patents are set to expire in…
Our recent trip to Stockholm and the Nordic Life Science Days conference was quite enlightening, especially as we publicly discuss drug prices (yet again). One presentation at NLSD by SwedenBio enlightened us on how…
In our last post, we presented a model which helps us aggregate a series of variables which, in turn, help us understand why certain therapeutic areas or indications are of greater interest from a licensing perspective than others.
Our aim with this model is to help companies with licenseable assets to frame their “stories” in a way which is compatible with how potential partners approach evaluation and decision-making.
Our first attempt at applying this model is for the HIV/AIDS market. During the 1990s, stories about AIDS were a daily occurrence on the nightly news. Images of celebrities fighting and dying from AIDS seemed to be everywhere. Rock Hudson, Freddy Mercury, Anthony Perkins…the list of celebrities who succumbed to complications from this disease seemed endless.
But what about today? Are there Unmet Needs which can be satisfied via novel therapeutics? And, if so, are they being funded and developed? Are there multinational companies with a stated interested in licensing these innovations once they are sufficiently mature?
In this post, we take a look at these questions.
A triumvirate is a three-person (or three-group) organization which is established for a specific administrative task(s). In Ancient Rome, the First Triumvirate was established between Julius Caesar, Pompey the…
Ample numbers of electrons will be spent discussing the BIO2016 conference in San Francisco last week, both positive and negative. Not wanting to be left out of the fun,…
Next week, our industry makes an unusual return trip to Union Square, as we return for another conference. This time, it's BIO. BIO is unlike other conferences on our circuit,…
There is an interesting article in the current issue of The Journal of Precision Medicine on Alzheimer's. The article attempts to answer a seemingly simple, yet complex question...Can systems biology…
Our friends at PharmaCircle recently published an interesting and provocative piece entitled Injectables: The New Oral? The PDF is available here. The article notes that, in 2014, seven of the…
How was Bio Europe in Stockholm last week? The Conference Itself – For us, the conference was terrific. We had nearly 30 high-quality meetings over the three days of partnering,…